– UK, London – Kings Arms Yard VCT PLC (LON: KAY) today announced the appointments of Swarupa Pathakji and Dr John Chiplin to its Board as Non-Executive Directors, effective from 1 November 2021.
Swarupa Pathakji will also join the Audit Committee as the next Chair.
The Board welcomes Swarupa and John and looks forward to working with them both over the coming years.
About Swarupa Pathakji
Swarupa has extensive experience across the financial sector, with an in-depth understanding of investment in growth companies, experience in exits and valuations. She qualified as a chartered accountant at Deloitte before spending time in mergers and acquisitions at Merrill Lynch. She moved to Duke Street, a mid-market Private Equity fund manager, in 2007 and has served as a non-executive Director on the Boards of several companies across multiple sectors. She is currently non-executive Director of OFS Holdings Ltd where she is chair of the Audit Committee.
About Dr. John Chiplin
John has extensive experience and expertise in the life sciences and technology sectors from both an operational and investment perspective. He is Chairman of Scancell Holdings plc, N4 Pharma plc, and Biotherapy Services Limited. He is also Managing Director of Newstar Ventures Ltd.
John was head of the ITI Life sciences investment fund in the UK and has managed the mergers, acquisitions and listing of a number of blue-chip companies. He also serves on the Boards of an Australian public company, Regeneus, and US private company Batu Biologics. He joins the Board at a time when increasing numbers of technology and healthcare investment opportunities are being considered and so his experience in these areas will be invaluable.
For more information: http://www.sparkvct.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
